Tag Archives: DES

ADAPT-DES: Proton Pump Inhibitors and Clopidogrel in Patients with DES

ADAPT-DES: Proton Pump Inhibitors and Clopidogrel in Patients with DES

Original Title: Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. The ADAPT-DES Study. Some proton pump inhibitors interfere with clopidogrel metabolism and could attenuate P2Y12 reception. Prior observational and randomized studies have reported contradicting results on the clinical significance of this drug interaction. The aim of this trial was

ABSORB III: Everolimus Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had

Prasugrel in the Treatment of Clopidogrel Nonresponders Undergoing PCI

Original Title: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention (RECLOSE-3 study). Reference: Valenti R, et al. JACC Cardiovasc Interv. 2015 Oct;8(12):1563-70. Clopidogrel Nonresponders have higher risk of adverse events (cardiovascular death and stent thrombosis) compared to responders. Studies published so far have failed to demonstrate the use of platelet function tests in ACS patient

Surgery vs. PCI in Diabetic Patients with Multivessel Disease

Original Title: Revascularization in diabetics with multivessel disease: a population-based evaluation of outcomes. Presenter: Ramanathan K. Real-world data support the role of CABG over PCI in diabetic patients with multivessel disease. However, PCI continues to be a common ­­­­­­option for this patient population, according to an analysis of 2 Canadian registries. Sourcing data from 2

IVUS-XPL: IVUS superior to angiography for guiding DES implantation in long lesions

Original Title: Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. Presenter: Hong S-J. Patients with long coronary lesions have better clinical results after a year of second generation DES implantation when interventions are guided by IVUS, instead of angiography. The benefit was attributed to a lower revascularization rate of ischemia

Polymer Free Drug Coated Stent in High Bleeding Risk Patients with Only One Month DAPT

Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N Engl J Med. 2015 Oct 14. [Epub ahead of print]. High bleeding risk patients undergoing PCI usually receive conventional bare metal stents (BMS) to allow the shortest possible DAPT (dual antiplatelet therapy), usually a month long. This

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI, according to this meta-analysis simultaneously published in the European Heart Journal. They analyzed data from 33.435 patients (mean age 64; 24% women) with a history of infarction included in one of the following clinical trials: CHARISMA, PRODIGY, ARCTIC-Interruption,

Top